GGrantIndex
← Leaderboards

Richard Malley

Brigham And Women'S Hospital

$13,476,616
Attributed
$13,476,616
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,253,396 · 8

By mechanism

R01$12,062,318 · 4
U19$5,038,678 · 2
R56$649,120 · 1
K08$503,280 · 1

Top collaborators

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Immunization

Research focus

ImmunizationImmunityStreptococcus PneumoniaeCellsSerotypingProteinsT-LymphocyteResponseAntigensAntibodiesPolysaccharidesBaseCd4 Positive T LymphocytesImmune ResponseMediatingVaccinesSuccessLaboratoriesConjugate VaccinesBacteriaChildCytokinePneumococcal InfectionsExtracellular

Grant awards (27)

Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)$4,776,780
U19 · FY2025 · AI · contact PI
Administrative Core: Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity (IMPACT-CETR)$261,898
U19 · FY2025 · AI · contact PI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine$1,144,476
R01 · FY2022 · AI · contact PI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine$1,153,542
R01 · FY2021 · AI · contact PI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine$1,067,677
R01 · FY2020 · AI · contact PI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine$1,076,287
R01 · FY2019 · AI · contact PI
Optimization and preclinical development of a TB Multiple Antigen Presenting System (MAPS) vaccine$1,439,101
R01 · FY2018 · AI · contact PI
Enhancing neonatal immunity to Streptococcus pneumoniae$396,500
R01 · FY2016 · AI · contact PI
Enhancing neonatal immunity to Streptococcus pneumoniae$396,500
R01 · FY2015 · AI · contact PI
S. pneumoniae pilus regulation and host response$649,120
R56 · FY2014 · AI · contact PI
Enhancing neonatal immunity to Streptococcus pneumoniae$496,442
R01 · FY2014 · AI · contact PI
Enhancing neonatal immunity to Streptococcus pneumoniae$372,710
R01 · FY2013 · AI · contact PI
Enhancing neonatal immunity to Streptococcus pneumoniae$415,000
R01 · FY2012 · AI · contact PI
Mechanisms of Immunity to Pneumococcal Colonization$406,225
R01 · FY2011 · AI · contact PI
Mechanisms of Immunity to Pneumococcal Colonization$410,329
R01 · FY2010 · AI · contact PI
Pneumococcal immunization through a novel mechanism$398,429
R01 · FY2010 · AI · contact PI
Mechanisms of Immunity to Pneumococcal Colonization$414,473
R01 · FY2009 · AI · contact PI
Pneumococcal immunization through a novel mechanism$402,453
R01 · FY2009 · AI · contact PI
Mechanisms of Immunity to Pneumococcal Colonization$414,473
R01 · FY2008 · AI · contact PI
Pneumococcal immunization through a novel mechanism$402,453
R01 · FY2008 · AI · contact PI
Mechanisms of Immunity to Pneumococcal Colonization$422,500
R01 · FY2007 · AI · contact PI
Pneumococcal immunization through a novel mechanism$410,248
R01 · FY2007 · AI · contact PI
Pneumococcal immunization through a novel mechanism$422,500
R01 · FY2006 · AI · contact PI
Pneumolysin, Innate and Acquired Immunity to Pneumococci$128,520
K08 · FY2005 · AI
Pneumolysin, Innate and Acquired Immunity to Pneumococci$128,520
K08 · FY2004 · AI
Pneumolysin, Innate and Acquired Immunity to Pneumococci$128,520
K08 · FY2003 · AI
Pneumolysin, Innate and Acquired Immunity to Pneumococci$117,720
K08 · FY2002 · AI